{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-041230","form_type":"8-K","ticker":null,"cik":"0000727207","company_name":"Accelerate Diagnostics, Inc","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.772170+00:00","generated_at":"2026-06-04T05:37:22.845470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Accelerate Diagnostics reports Q4 net loss $13M, full-year net loss $61.6M; Wave trials planned Q2 2024","bullets":["Q4 net sales $3.0M flat YoY; full-year net sales $12.1M down 5% from $12.8M.","Q4 gross margin 21% vs 28% YoY; full-year 21% vs 26%, including $1.2M inventory write-down.","Q4 net loss $13.0M ($0.89/share); full-year net loss $61.6M ($4.94/share).","Cash used Q4 $7.9M, full-year $46.3M; year-end cash $13.2M.","Wave AST system clinical trials on track for Q2 2024; ~90% customer interest in adoption."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-041230","json":"https://secwatch.observer/filing/0001104659-24-041230.json","markdown":"https://secwatch.observer/filing/0001104659-24-041230.md","text":"https://secwatch.observer/filing/0001104659-24-041230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727207/000110465924041230/0001104659-24-041230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727207/000110465924041230/tm2410254d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:37:22.845470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f31bb78596159dd059f609f0cea07f18012547c5","claim":"Accelerate Diagnostics, Inc reported financial results for the quarter and full-year ending December 31, 2023.","evidence_excerpt":"On March 28, 2024, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full-year ending December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465924041230/0001104659-24-041230-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full-year ending December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}